PPARG and non-small cell lung carcinoma: We recently found that rosiglitazone reducednicotine-induced NSCLC cell growth through downregulation of α7 nAChR-dependent signals including ERKand p38 MAPK; this effect appeared to be PPARγ-independent (Han et al., unpublished data).